3 articles
Novo Nordisk shares gained 24.9% over 30 days through Q1 2026, outperforming the broader pharma sector. The company licensed its Parkinson's cell therapy to AI-native partner Cellular Intelligence while shutting its internal unit, redirecting capital to its high-margin GLP-1 franchise. The move reflects a wider big-pharma trend of outsourcing experimental modalities to AI-enabled specialists.
Jade Biosciences expects to launch Phase 1 trials for JADE301, a monoclonal antibody targeting autoimmune diseases, by March 31, 2027. The clinical milestone represents a key catalyst for the pre-revenue biotech as it advances its pipeline of potentially best-in-class therapeutics.
GSK is positioning Depemokimab, its ultra-long-acting anti-IL-5 biologic, for a late 2027 commercial launch in the rapidly expanding asthma therapeutics market. The pipeline milestone represents a significant revenue catalyst for the British pharma giant as it competes for dominance in a market projected to exceed $16 billion. Investors are watching the asset closely as a potential differentiator in GSK's respiratory franchise.